Fenebrutinib, Genentech’s investigational BTK inhibitor, was found to significantly reduce relapse rates compared with the approved therapy Aubagio (teriflunomide) in two Phase 3 clinical trials involving people with relapsing forms of multiple sclerosis (MS). Positive top-line results from one of those trials, FENhance 2 (NCT04586023), were announced late last year. Now, Genentech has reported that […]
The post Fenebrutinib again bests Aubagio in trial at cutting MS relapse rates appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com